DUBLIN, Ireland, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that Sev Melkonian has joined the company as Vice President of Patient Services, Distribution, and Reimbursement. Mr. Melkonian has extensive industry experience building and leading healthcare operations and patient support service teams across global healthcare and biopharmaceutical organizations. "We are thrilled to ...

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE .High beta parts of the market sold off significantly last week as the yield on the 10-Year Treasury continued to climb and closed Friday over the 4.75% threshold. The small cap Rus ...

Growth Stock Forum Overview - The Growth Stock Forum focuses on identifying attractive risk/reward opportunities in growth stocks, particularly in the biotech sector [1] - The forum provides a model portfolio of 15-20 stocks that are updated regularly, along with a top picks list of up to 10 stocks expected to perform well in the current year [2] - Members have access to trading ideas targeting both short-term and medium-term moves, as well as community dialogue and Q&A [2] Avadel Pharmaceuticals Performance - Avadel Pharmaceuticals (NASDAQ: AVDL) shares hit new 52-week lows following the release of preliminary Q4 numbers and 2025 guidance [2] - The 2025 guidance was significantly below expectations due to changes in the patient mix [2] Analyst and Platform Disclosures - The analyst has no stock, option, or derivative positions in any mentioned companies and no plans to initiate such positions within the next 72 hours [3] - The article reflects the analyst's personal opinions and is not influenced by compensation or business relationships with mentioned companies [3] - Seeking Alpha emphasizes that past performance does not guarantee future results and does not provide personalized investment advice [4] - The platform's analysts include both professional and individual investors who may not be licensed or certified by any regulatory body [4]

Revenue and Financial Performance - LUMRYZ net revenue for Q4 2024 estimated at $50.0 million, a 150% increase compared to $19.5 million in Q4 2023[1] - Full-year 2024 net product revenue of approximately $169.0 million, up from $28.0 million in 2023[7] - 2025 net product revenue guidance for LUMRYZ is $240–$260 million, representing 50% year-over-year growth at the midpoint[1] - Cash, cash equivalents, and marketable securities totaled $73.0 million as of December 31, 2024[7] Patient Metrics and Therapy Adoption - 2,500 patients on LUMRYZ as of December 31, 2024, including 600 new patients initiating therapy in Q4[1] - 74% of patients on LUMRYZ therapy were reimbursed as of December 31, 2024[12] - 2025 guidance includes 2,800–3,000 new patient initiations and 3,300–3,500 total patients on therapy by December 31, 2025[12] Sales and Market Expansion - Expanded field sales team by nearly 15% to target under-penetrated prescribers[12] Research and Development - Phase 3 REVITALYZ study for idiopathic hypersomnia expected to complete in H2 2025[12] - Preclinical development ongoing for a low-/no-sodium oxybate formulation bioequivalent to LUMRYZ[12]

-- Approximately $50.0 million of net revenue from sales of LUMRYZ™ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for the comparable period in 2023 -- --2,500 patients on LUMRYZ as of December 31, 2024, including 600 patients that initiated therapy in the fourth quarter -- -- LUMRYZ net product revenue of $240 – $260 million in 2025, representing 50% year-over-year growth at the midpoint -- -- Management to host a conference call today at 4:30 p.m. ET -- DUBLIN, Ireland, ...

DUBLIN, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to twelve (12) new employees to purchase an aggregate of 131,700 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with Avadel in accordance wit ...

DUBLIN, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, January 8, 2025, to provide a corporate update and discuss the Company's preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2024. A live audio webcast of the call can be accessed by visiting the investo ...

DUBLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20 at 7:30 a.m. GMT / 2:30 a.m. ET. A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel's Investor Relations website, investors.avadel.com, for 90 day ...

Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Austin Murtagh - Director, Precision AQ Greg Divis - CEO Richard Kim - CCO Jennifer Gudeman - SVP, Medical & Clinical Affairs Tom McHugh - CFO Conference Call Participants Andrew Tsai - Jefferies François Brisebois - Oppenheimer Oren Livnat - H.C. Wainwright Ami Fadia - Needham David Amsellem - Piper Sandler Operator Good day everyone and welcome to today's Avadel Pharmaceuticals 3Q 20 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— Title of each class Trading Symbol(s) Name of each exchange on which registered Ordinary Shares, nominal value $0.01 per share AVDL The Nasdaq Global Market FORM 10-Q ——————— ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition per ...